08:25 EDT eFFECTOR Therapeutics trading halted, news pending
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EFTR:
- Effector Therapeutics’ Stock Issuance Capped: Navigating the Lincoln Park Agreement’s Exchange Limit
- eFfector Therapeutics reports Q4 EPS ($3.42), consensus ($1.65)
- eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- EFTR Earnings this Week: How Will it Perform?
- eFfector Therapeutics target adjusted to $24 at H.C. Wainwright